Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSGJ-707 + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**SSGJ-707 + capecitabine + oxaliplatin** is an investigational combination regimen for cancer treatment. SSGJ-707 is a bispecific antibody that targets both **PD-1** and **VEGF**, designed using 3SBio’s CLF2 platform. It is being studied in combination with the established chemotherapy regimen XELOX (capecitabine plus oxaliplatin). Capecitabine is an oral fluoropyrimidine antimetabolite that is metabolized to 5-fluorouracil, interfering with DNA synthesis, while oxaliplatin is a platinum-based chemotherapeutic that induces DNA crosslinking and apoptosis in rapidly dividing cancer cells. The combination seeks to leverage immune checkpoint blockade and angiogenesis inhibition with cytotoxic chemotherapy, primarily for metastatic colorectal cancer and non-small cell lung cancer[1][2][5][6][7].
- Brand names
- XELOXCAPOX
- Other names
- SSGJ-707 + capecitabine + oxaliplatin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on SSGJ-707 + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSGJ-707 + capecitabine + oxaliplatin.